Blogger Widgets ReportsnReports: Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma

Sunday 11 December 2011

Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma


GBI Research, the leading business intelligence provider, has released its latest research “Endpoints- Clinical Trials in Orphan Diseases” which provides an insight into different endpoints that are used in clinical trials relating to orphan diseases. The report examines different aspects under clinical trial endpoints in orphan diseases such as analysis on major marketed orphan drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising orphan drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the orphan drugs of different companies.
Scope
  • The report details the clinical trial endpoints in orphan diseases. The report covers:
  • Data and analysis on the marketed products and analysis of their efficacy and safety details
  • Analysis of the five major orphan diseases which include Huntington's Disease, Acute Myelocytic Leukemia, Amyptrophic Lateral Sclerosis, Hodgkin Lymphoma, Multiple Myeloma, Ovarian Cancer and Pancreatic Cancer.
  • Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
  • Analysis on most promising molecules of seven major orphan diseases with emphasis on their efficacy and safety details.
  • Company Profiling talks in detail about the companies, which are strong in the market
Reasons to Buy
  • The report will help business development and marketing executives who are strategizing their product launches to:
  • Understand the trends in clinical trial endpoints used for orphan diseases
  • Build effective strategies to launch their pipeline products by identifying the right endpoints
  • Understanding and applying Surrogate endpoints and Clinical Biomarkers as endpoints for orphan diseases
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.

No comments:

Post a Comment